Nureca Ltd

Nureca Ltd has manually filed a disclosure under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. This action was taken because a designated person acquired shares, but the transaction was not reflected in the system-driven disclosure mechanism of the stock exchanges. Despite checking with the exchanges, a conclusive resolution has not been reached. As a precautionary measure to ensure regulatory compliance, the company has made this disclosure manually. The filing details the purchase of equity shares by a promoter group member on various dates in July and early August 2026.

Nureca Ltd has provided additional details regarding a corporate announcement dated August 7, 2026. This clarification pertains to a Final Order of Rectification received under Section 161 of the CGST Act, 2017, on August 6, 2026. The order relates to the tax period 2021-22. The settlement involves the reversal of Input Tax Credit (ITC) amounting to ₹15,40,311. The company states that this settlement has no adverse impact on its financial position, as it only involves the reversal of ITC.

Nureca Ltd has received a Final Order of Rectification from the CGST Act, 2017 authority, concluding a pending tax matter for the 2021-22 period. The dispute has been resolved through the reversal of Input Tax Credit (ITC) amounting to ₹15,40,311. The company has confirmed that this settlement results in no further demand, and the matter is now officially disposed of. This disclosure is made in compliance with SEBI regulations.

Nureca Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on July 21, 2026. The company operates in the 'Home healthcare and wellness products' segment. The limited review reports from the statutory auditors have been submitted, expressing an unmodified opinion. The filing also references past events including a scheme of merger and a share buyback.

Nureca Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved the results in a meeting held on July 21, 2026. The company operates in the home healthcare and wellness products segment. The limited review report from the statutory auditors has been enclosed, expressing an unmodified opinion.

Nureca Ltd has announced that its Board of Directors will convene on Tuesday, July 21, 2026. The primary agenda for this meeting is to consider and approve the un-audited financial results, both standalone and consolidated, for the first quarter ended June 30, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nureca Limited has filed a disclosure regarding an inter-se transfer of 32,19,113 equity shares among its promoter and promoter group. This transaction qualifies for an exemption under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations. The transfer involved Saurabh Goyal acquiring shares from Payal Goyal and Aryan Goyal, resulting in a significant increase in Saurabh Goyal's shareholding from 34.35% to 68.09%. The acquisition price per share was not disclosed in this filing. The report was filed with the stock exchanges four working days prior to the acquisition date, adhering to SEBI regulations.

Nureca Ltd has filed a disclosure regarding a substantial acquisition of shares by Saurabh Goyal, the sole promoter. The transaction involves an inter-se transfer of shares amongst promoters and the promoter group, executed as part of a family settlement agreement. This acquisition is made in reliance upon an exemption provided under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, thus exempting the acquirer from making an open offer. Saurabh Goyal's shareholding post-transaction has increased to 34.35% of the total share capital.

Nureca Ltd has resubmitted a more legible copy of its 10th Annual General Meeting (AGM) notice and Annual Report for the 2025-26 fiscal year. This resubmission, originally filed on July 3, 2026, is purely for clarity and convenience for the stock exchange and shareholders, with no changes to the original content. The filing includes details on corporate overview, chairman's statement, board of directors, management discussion and analysis, director's report, corporate governance, and standalone/consolidated financial statements. The company highlighted a significant operational turnaround in FY26, achieving an operating profit of ₹8.5 Cr compared to a loss in FY25, driven by enhanced efficiencies. However, a loss was incurred in Q4 FY26 due to fair value changes and net loss on investments.

Nureca Ltd announced that the Exchange has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, from Saurabh Goyal. The disclosure pertains to the acquisition of equity shareholding and voting rights by Saurabh Goyal, a Promoter of the company, pursuant to a Family Settlement Agreement dated June 17, 2026. The transaction involved the transfer of 32,19,113 equity shares, increasing his total holding to 64,97,169 shares, representing 68.09% of the total voting capital. The company stated that the shareholding of the Promoter and Promoter group remains unchanged overall, with detailed pre and post-transaction shareholding attached as Annexure I.